

IN THE SPECIFICATION:

Please amend the paragraph beginning at page 7, line 9 as follows:

FIG. 10 shows ~~a probe to be~~ probes used in Example 3 of the present invention for amplifying DRB*15 and DRB*16. The sequences of the three regions of DRB*15 shown in FIG. 10 are set forth in SEQ ID NOS: 3, 4 and 8, respectively. The sequence of nucleotides 130-187 of DRB*16, shown in FIG. 10, is set forth in SEQ ID NO: 5.

Please amend the paragraph beginning at page 8, line 8 as follows:

The term "polymorphism site" used herein is a site whose nucleotide sequence differs between polymorphism genes. For example, if the nucleotide sequence of a polymorphism gene A1 is AAA TTT (CCC) GGG (SEQ ID NO: 1) and the nucleotide sequence of a polymorphism gene A2 is AAA TTT (AGT), GGG (SEQ ID NO: 2), the site bracketed by parentheses corresponds to the polymorphism site. If a single nucleotide differs in the polymorphism site, such a polymorphism is particularly designated as a "single nucleotide polymorphism".

Please amend the paragraph at page 41, line 9 as follows:

In this example, the type of polymorphism sequence showing an allo antigenicity to region DRB1 of HLA class II is determined. DRB1*15 and DRB1*16 are subtypes of DT2. DRB1*15 (~~Sequence Number 1~~) and DRB1*16 (~~Sequence Number 2~~) differ only in 141st nucleotide (T→C) and 180th nucleotide (G→C).